SXTPW — 60 Degrees Pharmaceuticals, Inc. Warrant
NASDAQ · Healthcare · Biotechnology
$0.04
+$0.00 (+0.00%)
60 Degrees Pharmaceuticals, Inc. Warrant (SXTPW) is a biotechnology company listed on NASDAQ. It is with about 2 employees. 60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
Latest reported SXTPW revenue for 2025-09-30 was $437.6K. Net income was -$2.3M. Revenue was up 333.6% from 2025-06-30 to 2025-09-30.
Use this SXTPW page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SXTPW quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SXTPW SEC filings page. Lician reads the product cache first so this HTML stays unique to 60 Degrees Pharmaceuticals, Inc. Warrant even when a live quote feed is slow.
About 60 Degrees Pharmaceuticals, Inc. Warrant
60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.
SXTPW Key Statistics
Market Cap
$0.00M
Volume
3,177
Previous Close
$0.04
Day Range
$0.04 – $0.04
EPS
-$18.55
Revenue
$607.57K
Net Income
-$7.96M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+139.6%
Profit Margin
-1309.4%
Employees
2
SXTPW Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $607.57K | $253.57K | $223.21K |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$7.96M | -$3.81M | -$6.18M |
| EPS (Diluted) | -$18.55 | -$59.18 | -$2.61 |
Total Assets
$5.76M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$1.66M
Operating Cash Flow
-$5.65M
Free Cash Flow
$0.00
60 Degrees Pharmaceuticals, Inc. Warrant Company Information
- IPO / Founded
- 2023-07-12
- Sector
- Healthcare
- Industry
- Biotechnology